FSTL1 and breast cancer: In particular, FSTL1 increases oncogenesis in BC by enhancing stemness and chemoresistance to doxorubicin and cisplatin through its ability to activate the integrin β3/Wnt/β-catenin signalling axis in TNBC cells [73].